Skip to Main Content

INFORMATION FOR

Silvio Inzucchi, MD

Professor of Medicine (Endocrinology)

Contact Information

Silvio Inzucchi, MD

Mailing Address

  • Endocrinology

    PO Box 208020, 333 Cedar Street

    New Haven, CT 06520-8056

    United States

Research Summary

Dr. Inzucchi’s research primarily involves clinical investigations into (1) the cardiovascular complications of diabetes, (2) insulin resistance and atherosclerosis, and (3) the inpatient management of hyperglycemia.

Coauthors

Research Interests

Diabetes Mellitus; Endocrinology; Hyperglycemia; Insulin Resistance; Metabolism; Atherosclerosis

Selected Publications

  • Blood Pressure and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: DELIVERSelvaraj S, Vaduganathan M, Claggett B, Miao Z, Fang J, Vardeny O, Desai A, Shah S, Lam C, Martinez F, Inzucchi S, de Boer R, Petersson M, Langkilde A, McMurray J, Solomon S. Blood Pressure and Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: DELIVER JACC Heart Failure 2023, 11: 76-89. DOI: 10.1016/j.jchf.2022.09.002.
  • Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV TrialWojeck B, Inzucchi S, Neeland I, Mancuso J, Frederich R, Masiukiewicz U, Cater N, McGuire D, Cannon C, Yaggi H. Ertugliflozin and Incident Obstructive Sleep Apnea: An Analysis from the VERTIS CV Trial Sleep Medicine 2022, 100: s249-s250. DOI: 10.1016/j.sleep.2022.05.671.
  • RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasisBalasubramanian P, Wanner C, Ferreira J, Ofstad A, Elsaesser A, Zinman B, Inzucchi S. RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis Journal Of The Endocrine Society 2022, 6: a422-a422. PMCID: PMC9625761, DOI: 10.1210/jendso/bvac150.878.
  • IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HFAdamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF JACC Heart Failure 2022 DOI: 10.1016/j.jchf.2022.09.004.
  • Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HFYeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF European Heart Journal 2022, 43 DOI: 10.1093/eurheartj/ehac544.833.
  • Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk modelKondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model European Heart Journal 2022, 43 DOI: 10.1093/eurheartj/ehac544.869.
  • Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HFAdamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF European Heart Journal 2022, 43 DOI: 10.1093/eurheartj/ehac544.913.
  • 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCOREDINZUCCHI S, BHATT D, PITT B, SZAREK M, CANNON C, LEWIS J, RIDDLE M, KOSIBOROD M, CHERNEY D, DWYER J, SCIRICA B, BAILEY C, BANKS P, DIAZ R, RAY K, UDELL J, LOPES R, LEITER L, STEG P. 864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED Diabetes 2022, 71 DOI: 10.2337/db22-864-p.
  • Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trialFerreira J, Inzucchi S, Zinman B, Mattheus M, Meinicke T, Steubl D, Wanner C, Gotsch U. Effects of empagliflozin on uric acid levels and gout: observations from the EMPA-REG OUTCOME trial Diabetologie Und Stoffwechsel 2022, 17: s62-s62. DOI: 10.1055/s-0042-1746380.
  • Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trialSharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B, Wagner-Golbs A. Association of kidney and cardiovascular outcomes in patients with type 2 diabetes mellitus: insights from the EMPA-REG OUTCOME trial Diabetologie Und Stoffwechsel 2022, 17: s31-s32. DOI: 10.1055/s-0042-1746295.
  • Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOSAnam A, Inzucchi S. Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS 2022, 527-553. DOI: 10.1007/978-3-030-92589-5_26.
  • WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTIONLeasure A, Acosta J, Schwartz A, Forman R, Sharma R, de Havenon A, Falcone G, Inzucchi S, Kernan W, Sheth K. WORSE VASCULAR RISK FACTOR CONTROL IN PATIENTS WITH STROKE COMPARED TO PATIENTS WITH MYOCARDIAL INFARCTION Journal Of The American College Of Cardiology 2022, 79: 1504. DOI: 10.1016/s0735-1097(22)02495-0.
  • U.S. PATTERNS OF DRUG UTILIZATION AND PRESCRIPTION FILLS FOR PROVEN CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTSNargesi A, Clark C, Liu M, Chen L, Reddy A, Amodeo S, Oikonomou E, Suchard M, Lipska K, McGuire D, Lin Z, Inzucchi S, Krumholz H, Khera R. U.S. PATTERNS OF DRUG UTILIZATION AND PRESCRIPTION FILLS FOR PROVEN CARDIOPROTECTIVE ANTI-HYPERGLYCEMIC AGENTS Journal Of The American College Of Cardiology 2022, 79: 1446. DOI: 10.1016/s0735-1097(22)02437-8.
  • Abstract 13948: Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United StatesSangha V, Lipska K, Lin Z, Inzucchi S, McGuire D, Krumholz H, Khera R. Abstract 13948: Patterns of Prescribing Sodium-Glucose Cotransporter-2 Inhibitors for Medicare Beneficiaries in the United States Circulation 2021, 144: a13948-a13948. DOI: 10.1161/circ.144.suppl_1.13948.
  • Abstract 13846: Prognostic Value of Echocardiographic Markers of Diastolic Dysfunction for Heart Failure in Overweight and Obese Patients in CAMELLIA-TIMI 61Gong J, Scirica B, Weissman N, Tang M, Inzucchi S, McGuire D, Keech A, Wiviott S, Sabatine M, Bohula E. Abstract 13846: Prognostic Value of Echocardiographic Markers of Diastolic Dysfunction for Heart Failure in Overweight and Obese Patients in CAMELLIA-TIMI 61 Circulation 2021, 144: a13846-a13846. DOI: 10.1161/circ.144.suppl_1.13846.
  • Abstract 13569: A Composite Score Summarizing Use And Dosing Of Evidence-based Medical Therapies In Heart Failure: Application To The DAPA-HF TrialDewan P, Bengtsson O, Docherty K, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, Biering-srensen T, Vaduganathan M, Defilippis E, Fiuzat M, McMurray J. Abstract 13569: A Composite Score Summarizing Use And Dosing Of Evidence-based Medical Therapies In Heart Failure: Application To The DAPA-HF Trial Circulation 2021, 144: a13569-a13569. DOI: 10.1161/circ.144.suppl_1.13569.
  • ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIALSharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.
  • Effets de l’empagliflozine sur les marqueurs de la stéatose et de la fibrose hépatique et lien avec les résultats cardiorénaux dans l’étude EMPA-REG OUTCOMEHadjadj S, Kahl S, Ofstad A, Zinman B, Wanner C, Schüler E, Inzucchi S, Roden M. Effets de l’empagliflozine sur les marqueurs de la stéatose et de la fibrose hépatique et lien avec les résultats cardiorénaux dans l’étude EMPA-REG OUTCOME Annales D Endocrinologie 2021, 82: 269-270. DOI: 10.1016/j.ando.2021.08.045.
  • Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOMEWanner C, Nangaku M, Kraus B, Zinman B, Mattheus M, Ohneberg K, Hajmessaoud N, Zaoui P, Schmoor C, Inzucchi S. Médiateurs de l’effet du traitement par empagliflozine sur les résultats rénaux dans l’essai EMPA-REG OUTCOME Néphrologie & Thérapeutique 2021, 17: 339. DOI: 10.1016/j.nephro.2021.07.233.
  • 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME TrialKAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial Diabetes 2021, 70 DOI: 10.2337/db21-319-or.
  • 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOMEINZUCCHI S, WANNER C, FITCHETT D, ZINMAN B, ANKER S, MATTHEUS M, VEDIN O, HANTEL S, LUND S. 790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME Diabetes 2021, 70 DOI: 10.2337/db21-790-p.
  • 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling HyperglycemiaATHONVARANGKUL D, BAK L, ZHENG C, D’AMBROSI J, SINER J, HONIDEN S, INZUCCHI S. 873-P: Modified Insulin Infusion Protocol for COVID-19 Patients Is Safe and Effective for Controlling Hyperglycemia Diabetes 2021, 70 DOI: 10.2337/db21-873-p.
  • Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trialInzucchi, Zinman B, Wanner C, Fitchett D, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial Diabetologie Und Stoffwechsel 2021, 16: s51-s52. DOI: 10.1055/s-0041-1727465.
  • Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOMEKraus B, Weir, Bakris G, Mattheus M, Cherney D, Sattar N, Heerspink H, Ritter I, von Eynatten M, Zinman B, Inzucchi, Wanner C, Koitka-Webe A. Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME Diabetologie Und Stoffwechsel 2021, 16: s52. DOI: 10.1055/s-0041-1727466.
  • Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trialFitchett D, Inzucchi, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Empagliflozin reduces the total burden of cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial Diabetologie Und Stoffwechsel 2021, 16: s51. DOI: 10.1055/s-0041-1727464.
  • Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trialVaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.
  • Acute Myeloid Leukemia Leading to Central Diabetes InsipidusWojeck B, Gossmann M, Zeidan A, Inzucchi S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus Journal Of The Endocrine Society 2021, 5: a570-a571. PMCID: PMC8090637, DOI: 10.1210/jendso/bvab048.1163.
  • A Single Virtual Consult Reduces Severe Hyperglycemia in Patients Admitted with COVID19 InfectionAthonvarangkul D, Gunawan F, Gunawan F, Nagel K, Nagel K, Bak L, Bak L, Herold K, Hwang J, Jastreboff A, Kibbey R, Shulman G, Vatner D, Alausa J, Alausa J, Subair L, Subair L, Inzucchi S. A Single Virtual Consult Reduces Severe Hyperglycemia in Patients Admitted with COVID19 Infection Journal Of The Endocrine Society 2021, 5: a335-a335. PMCID: PMC8089507, DOI: 10.1210/jendso/bvab048.683.
  • Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac TransplantationBalasubramanian P, Moreau C, Ahmad T, Inzucchi S. Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac Transplantation Journal Of The Endocrine Society 2021, 5: a383-a383. PMCID: PMC8090379, DOI: 10.1210/jendso/bvab048.780.
  • Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 DiabetesDing Q, Qin L, Wojeck B, Inzucchi S, Ibrahim A, Bravata D, Strohl K, Yaggi H, Zinchuk A. Associations Between Polysomnographic Phenotypes of Obstructive Sleep Apnea and Incident Type 2 Diabetes 2021, a4679-a4679. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4679.
  • Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic SyndromeLupsa B, Inzucchi S. Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome 2021, 9-25. DOI: 10.1007/978-3-030-67455-7_2.
  • Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME TrialHamilton A, Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. Association of Kidney and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: Insights From the EMPA-REG OUTCOME Trial Heart Lung And Circulation 2021, 30: s212-s213. DOI: 10.1016/j.hlc.2021.06.259.
  • Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME TrialHamilton A, Fitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, Mattheus M, Vedin O, Hantel S, Lund S. Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial Heart Lung And Circulation 2021, 30: s220-s221. DOI: 10.1016/j.hlc.2021.06.278.
  • Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOMEHamilton A, Inzucchi S, Wanner C, Fitchett D, Zinman B, Anker S, Mattheus M, Vedin O, Hantel S, Lund S. Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME Heart Lung And Circulation 2021, 30: s221-s222. DOI: 10.1016/j.hlc.2021.06.281.
  • Abstract 14959: Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME TrialFitchett D, Zinman B, Inzucchi S, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Mattheus M, Vedin O, Hantel S, Lund S. Abstract 14959: Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14959.
  • Abstract 14960: Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME TrialFitchett D, Inzucchi S, Zinman B, Wanner C, Anker S, Pocock S, Kaspers S, George J, Johansen O, Jamal W, Hantel S, Lund S. Abstract 14960: Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME Trial Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14960.
  • Abstract 14962: Empagliflozin’s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOMEAnker S, Fitchett D, Zinman B, Ofstad A, Wanner C, Vedin O, Schinzel B, Yaggi H, George J, Sander L, Inzucchi S, Verma S. Abstract 14962: Empagliflozin’s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14962.
  • Abstract 16392: The Effect of Dapagliflozin on Anemia in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of DAPA-HFDocherty K, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Abstract 16392: The Effect of Dapagliflozin on Anemia in Patients With Heart Failure and Reduced Ejection Fraction: An Analysis of DAPA-HF Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.16392.
  • Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOMEVaduganathan M, Sattar N, Fitchett D, Ofstad A, Brueckmann M, George J, Verma S, Mattheus M, Wanner C, Inzucchi S, Zinman B, Butler J. Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME Circulation 2020, 142 DOI: 10.1161/circ.142.suppl_3.14849.
  • The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HFDewan P, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Lindholm D, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. The effect of dapagliflozin in patients with HFrEF and COPD: a post-hoc analysis of DAPA-HF European Heart Journal 2020, 41 DOI: 10.1093/ehjci/ehaa946.0932.
  • Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HFKristensen S, Docherty K, Jhund P, Bengtsson O, Demets D, Inzucchi S, Kober L, Kosiborod M, Langkilde A, Martinez F, Ponikowski P, Sabatine M, Sjostrand M, Solomon S, McMurray J. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF European Heart Journal 2020, 41 DOI: 10.1093/ehjci/ehaa946.0939.
  • 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM) Diabetes 2020, 69 DOI: 10.2337/db20-380-p.
  • 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME TrialNEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.
  • 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG OutcomeINZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.
  • 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment EffectsINZUCCHI S, KRAUS B, WEIR M, BAKRIS G, MATTHEUS M, CHERNEY D, SATTAR N, HEERSPINK H, RITTER I, EYNATTEN M, ZINMAN B, WANNER C, KOITKA-WEBER A. 132-LB: Implications of Initial EGFR Response to Empagliflozin Treatment Effects Diabetes 2020, 69 DOI: 10.2337/db20-132-lb.
  • 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical CenterBAK L, FANDEL T, BOZZO J, DEWITT M, CHEN P, PANDO R, FERRO L, KAPLAN R, HENDRICKSON K, AMPORT S, SUSSMAN L, INZUCCHI S. 23-OR: EHR-Based Blood Glucose Alerts Improve Inpatient Glycemic Control at a Large Academic Medical Center Diabetes 2020, 69 DOI: 10.2337/db20-23-or.
  • 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HFINZUCCHI S, DOCHERTY K, KOBER L, KOSIBOROD M, MARTINEZ F, PONIKOWSKI P, SABATINE M, SOLOMON S, BELOHLAVEK J, BÖHM M, CHIANG C, DE BOER R, DIEZ M, DUKAT A, LJUNGMAN C, VERMA S, DEMETS D, BENGTSSON O, LANGKILDE A, SJÖSTRAND M, JHUND P, MCMURRAY J. 271-OR: ADA Presidents’ Select Abstract: Effect of Dapagliflozin on the Incidence of Diabetes: A Prespecified Exploratory Analysis from DAPA-HF Diabetes 2020, 69 DOI: 10.2337/db20-271-or.
  • 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOMEVERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME Diabetes 2020, 69 DOI: 10.2337/db20-28-or.
  • 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOMEVADUGANATHAN M, SATTAR N, FITCHETT D, OFSTAD A, BRUECKMANN M, GEORGE J, VERMA S, MATTHEUS M, WANNER C, INZUCCHI S, ZINMAN B, BUTLER J. 30-OR: Empagliflozin Delays Need for Insulin Initiation in Patients with Type 2 Diabetes and Cardiovascular Disease: Findings from EMPA-REG OUTCOME Diabetes 2020, 69 DOI: 10.2337/db20-30-or.
  • 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4 Diabetes 2020, 69 DOI: 10.2337/db20-927-p.
  • SAT-258 Surprising Transformation of a Microprolactinoma to a MacroprolactinomaAthonvarangkul D, Hosier H, Wojeck B, Inzucchi S. SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma Journal Of The Endocrine Society 2020, 4: sat-258-. PMCID: PMC7207434, DOI: 10.1210/jendso/bvaa046.1057.
  • CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIALDocherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.
  • A Case of the Use of Genomic Signatures in the Diagnosis of Cushing DiseaseMurari K, Gossman M, Mahajan A, Erson Z, Inzucchi S, Omay S. A Case of the Use of Genomic Signatures in the Diagnosis of Cushing Disease Journal Of Neurological Surgery Part B Skull Base 2020, 81: s1-s272. DOI: 10.1055/s-0040-1702681.
  • Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF TrialKosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.
  • URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOMEVerma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.
  • HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDYVerma S, Böhm M, Brueckmann M, Fitchett D, George J, Inzucchi S, Marx N, Mattheus M, Ofstad A, Slawik J, Wanner C, Zinman B. HEART FAILURE OUTCOMES IN PATIENTS WITH DIABETES WITH AND WITHOUT ATRIAL FIBRILLATION - DATA FROM THE EMPA-REG OUTCOME STUDY Canadian Journal Of Cardiology 2019, 35: s197. DOI: 10.1016/j.cjca.2019.07.619.
  • P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular diseaseMcGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease European Heart Journal 2019, 40 DOI: 10.1093/eurheartj/ehz746.0869.
  • 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOMEZINMAN B, FITCHETT D, MATTHEUS M, WANNER C, GEORGE J, VEDIN O, INZUCCHI S, JOHANSEN O. 159-LB: Relationship between Hypoglycaemia (Hypo), Outcomes and Empagliflozin (EMPA) Treatment Effect in EMPA-REG OUTCOME Diabetes 2019, 68 DOI: 10.2337/db19-159-lb.
  • 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOMEINZUCCHI S, KHUNTI K, FITCHETT D, WANNER C, MATTHEUS M, GEORGE J, PERNILLE OFSTAD A, ZINMAN B. 19-LB: Consistent Cardiovascular (CV) Benefits from Empagliflozin across the Spectrum of CV Risk Factor Control: Post Hoc Analysis from EMPA-REG OUTCOME Diabetes 2019, 68 DOI: 10.2337/db19-19-lb.
  • 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME TrialINZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial Diabetes 2019, 68 DOI: 10.2337/db19-248-or.
  • Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1cWanner C, Cooper M, Inzucchi S, Zinman B, Zwiener I, Eynatten M, Koitka-Weber A. Empagliflozin Improves Kidney Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol and HbA1c Diabetologie Und Stoffwechsel 2019, 14: s80-s80. DOI: 10.1055/s-0039-1688342.
  • EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINEFitchett D, Inzucchi S, Sambevski S, Kaspers S, Pfarr E, George J, Zinman B. EMPAGLIFLOZIN REDUCES MORTALITY AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH OR WITHOUT A HISTORY OF MYOCARDIAL INFARCTION OR STROKE AT BASELINE Canadian Journal Of Cardiology 2018, 34: s80-s81. DOI: 10.1016/j.cjca.2018.07.288.
  • 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME TrialVerma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.
  • P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baselineFitchett D, Inzucchi S, Cannon C, McGuire D, Johansen O, Sambevski S, Hehnke U, George J, Zinman B. P1879Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline European Heart Journal 2018, 39 DOI: 10.1093/eurheartj/ehy565.p1879.
  • P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trialMcGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, George J, Elsasser U, Woerle H, Lund S, Fitchett D. P5334Effect of empagliflozin on cardiovascular events including recurrent events in the EMPA-REG OUTCOME trial European Heart Journal 2018, 39 DOI: 10.1093/eurheartj/ehy566.p5334.
  • What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.
  • Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at BaselineFITCHETT D, SCIRICA B, INZUCCHI S, CANNON C, MCGUIRE D, JOHANSEN O, SAMBEVSKI S, HEHNKE U, GEORGE J, ZINMAN B. Empagliflozin (EMPA) Reduces Mortality and Hospitalization for Heart Failure (HHF) Irrespective of Cardiovascular (CV) Risk Score at Baseline Diabetes 2018, 67 DOI: 10.2337/db18-1123-p.
  • Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative RegistryWONG N, SONG Y, ARNOLD S, SPERLING L, CANNON C, INZUCCHI S, KOSIBOROD M. Composite Cardiovascular Risk Factor Target Achievement and Its Indicators in U.S. Adults with Diabetes—The Diabetes Collaborative Registry Diabetes 2018, 67 DOI: 10.2337/db18-1487-p.
  • Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE CohortRASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.
  • Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1cWANNER C, COOPER M, INZUCCHI S, ZINMAN B, HEHNKE U, EYNATTEN M, KOITKA-WEBER A. Empagliflozin Improves Renal Outcomes Irrespective of Control of Blood Pressure, Low-Density Lipoprotein Cholesterol, and HbA1c Diabetes 2018, 67 DOI: 10.2337/db18-524-p.
  • SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIALRuggenenti P, Inzucchi S, Zinman B, Hantel S, Koitka-Weber A, von Eynatten M, Wanner C. SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME® TRIAL Nephrology Dialysis Transplantation 2018, 33: i487-i487. DOI: 10.1093/ndt/gfy104.sp415.
  • CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOMEInzucchi S, Zinman B, McGinniss J, Schnee J, George J, Fitchett D. CONSISTENT EFFECT OF EMPAGLIFLOZIN ON COMPOSITE OUTCOMES RELATED TO HEART FAILURE: RESULTS FROM EMPA-REG OUTCOME Journal Of The American College Of Cardiology 2017, 69: 1656. DOI: 10.1016/s0735-1097(17)35045-3.
  • Abstract 013: Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the Iris Trial on Improving Outcomes in Patients With Cerebrovascular DiseaseArnold S, Inzucchi S, Tang F, McGuire D, Mehta S, Maddox T, Goyal A, Sperling L, Einhorn D, Wong N, Kosiborod M. Abstract 013: Using the Diabetes Collaborative Registry (DCR) to Estimate the Potential Real-world Impact of the Iris Trial on Improving Outcomes in Patients With Cerebrovascular Disease Circulation Cardiovascular Quality And Outcomes 2017, 10 DOI: 10.1161/circoutcomes.10.suppl_3.013.
  • Abstract 135: Assessing the Personalization of Glycemic Management Strategies Through the Diabetes Collaborative RegistryArnold S, Inzucchi S, McGuire D, Tang F, Mehta S, Goyal A, Sperling L, Maddox T, Einhorn D, Wong N, Hammer N, Fenici P, Sheehan J, Kosiborod M. Abstract 135: Assessing the Personalization of Glycemic Management Strategies Through the Diabetes Collaborative Registry Circulation Cardiovascular Quality And Outcomes 2017, 10 DOI: 10.1161/circoutcomes.10.suppl_3.135.
  • Abstract 74: Obesity and the Risk of Recurrent Vascular Events in Patients with Ischemic Stroke: Insights from the Insulin Resistance Intervention after Stroke (IRIS) TrialDearborn J, Viscoli C, Inzucchi S, Young L, Kernan W. Abstract 74: Obesity and the Risk of Recurrent Vascular Events in Patients with Ischemic Stroke: Insights from the Insulin Resistance Intervention after Stroke (IRIS) Trial Stroke 2017, 48 DOI: 10.1161/str.48.suppl_1.74.
  • How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination TherapiesInzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies 2016, 471-492. DOI: 10.1002/9781118924853.ch33.
  • 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular RiskFitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. 10 Effect of Empagliflozin on Mortality and Causes of Death in Patients with Type 2 Diabetes at High Cardiovascular Risk Canadian Journal Of Diabetes 2016, 40: s4-s5. DOI: 10.1016/j.jcjd.2016.08.013.
  • EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIALFitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR MORTALITY BY PREVALENT OR INCIDENT HEART FAILURE IN THE EMPA-REG OUTCOME TRIAL Canadian Journal Of Cardiology 2016, 32: s90-s91. DOI: 10.1016/j.cjca.2016.07.124.
  • EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOMEFitchett D, Zinman B, Lachin J, Mattheus M, George J, Johansen O, Inzucchi S. EFFECTS OF EMPAGLIFLOZIN ON OVERALL HEART FAILURE BURDEN IN EMPA-REG OUTCOME Canadian Journal Of Cardiology 2016, 32: s175-s176. DOI: 10.1016/j.cjca.2016.07.272.
  • EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISKFitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.
  • LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGELee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.
  • Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia 2012, 56: 680-680. DOI: 10.1007/s00125-012-2785-9.
  • Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379Matthews D, Inzucchi S, . Response to Comments on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 Diabetes Care 2012, 35: e72-e73. PMCID: PMC3447838, DOI: 10.2337/dc12-1184.
  • Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M, Peters A, Tsapas A, Wender R, Matthews D. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Spectrum 2012, 25: 154-171. DOI: 10.2337/diaspect.25.3.154.
  • THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDYHage F, Wackers F, Bansal S, Chyun D, Young L, Inzucchi S, Iskandrian A. THE HEART RATE RESPONSE TO ADENOSINE AS A PREDICTOR OF ADVERSE CARDIAC OUTCOMES IN THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS STUDY Journal Of The American College Of Cardiology 2012, 59: e1162. DOI: 10.1016/s0735-1097(12)61163-2.
  • 236 Type 1 Diabetes MellitusInzucchi S, Sherwin R. 236 Type 1 Diabetes Mellitus 2012, e78-e94. DOI: 10.1016/b978-1-4377-1604-7.00561-3.
  • 237 Type 2 Diabetes MellitusInzucchi S, Sherwin R. 237 Type 2 Diabetes Mellitus 2012, 1489-1499. DOI: 10.1016/b978-1-4377-1604-7.00237-2.
  • SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDYTandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.
  • Continuous Glucose MonitoringInzucchi S, Rosenstock J, Umpierrez G. Continuous Glucose Monitoring The Journal Of Clinical Endocrinology & Metabolism 2010, 95: e1-e1. DOI: 10.1210/jcem.95.10.9998.
  • CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIALBansal S, Wackers F, Inzucchi S, Young L, Chyun D. CARDIAC OUTCOMES AFTER SCREENING FOR ASYMPTOMATIC CORONARY ARTERY DISEASE IN PATIENTS WITH METABOLIC SYNDROME: POST-HOC ANALYSIS OF THE DIAD TRIAL Journal Of The American College Of Cardiology 2010, 55: a141.e1325. DOI: 10.1016/s0735-1097(10)61326-5.
  • Management of Diabetes and Hyperglycemia in the Hospital SettingDeMauro-Jablonski S, Inzucchi S. Management of Diabetes and Hyperglycemia in the Hospital Setting 2009, 773-786. DOI: 10.1007/978-0-387-09841-8_47.
  • Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09Inzucchi S, Leiter L, Rosenstock J. Diabetes de Tipo 2 y las TZD (Tiazolidinedionas) Fritz 9.24.09 The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e1-e1. DOI: 10.1210/jcem.94.11.9987.
  • Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09Inzucchi S, Leiter L, Rosenstock J. Type 2 Diabetes and TZDs (Thiazolidinediones) Fritz 9.24.09 The Journal Of Clinical Endocrinology & Metabolism 2009, 94: e2-e2. DOI: 10.1210/jcem.94.11.9988.
  • Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?—ReplyKosiborod M, Inzucchi S, Krumholz H, Masoudi F, Goyal A, Spertus J. Is Insulin the Preferred Compound in Lowering Glucose Levels in Patients After a Myocardial Infarction?—Reply JAMA Internal Medicine 2009, 169: 1633-1638. DOI: 10.1001/archinternmed.2009.327.
  • Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exerciseRosenstock J, Inzucchi S, Seufert J, Fleck P, Wilson C, Mekki Q. Combination alogliptin plus pioglitazone treatment in patients with type 2 diabetes inadequately controlled with diet exercise Canadian Journal Of Diabetes 2009, 33: 212. DOI: 10.1016/s1499-2671(09)33076-2.
  • Cardiovascular risk-benefit ratio of thiazolidinedionesLipska K, Inzucchi S. Cardiovascular risk-benefit ratio of thiazolidinediones Current Cardiovascular Risk Reports 2008, 3: 42-50. DOI: 10.1007/s12170-009-0008-9.
  • Abstract 3230: Elevated Glucose and Mortality in Patients Hospitalized with Heart FailureKosiborod M, Inzucchi S, Spertus J, Wang Y, Masoudi F, Havranek E, Krumholz H. Abstract 3230: Elevated Glucose and Mortality in Patients Hospitalized with Heart Failure Circulation 2008, 118 DOI: 10.1161/circ.118.suppl_18.s_1117-b.
  • Standards of Medical Care in Diabetes—2008 Response to Dora, Kramer, and CananiHirsch I, Inzucchi S, Kirkman M. Standards of Medical Care in Diabetes—2008 Response to Dora, Kramer, and Canani Diabetes Care 2008, 31: e45-e45. DOI: 10.2337/dc08-0285.
  • Abstract 3529: Feasibility, Effectiveness and Safety of Intensive Glucose Control in Critically Ill Hyperglycemic Patients Hospitalized With Acute Coronary SyndromesKosiborod M, Inzucchi S, Hamburg M, Riggs L, Koshy S, Krumholz H, Xiao L, Khalid A, Spertus J. Abstract 3529: Feasibility, Effectiveness and Safety of Intensive Glucose Control in Critically Ill Hyperglycemic Patients Hospitalized With Acute Coronary Syndromes Circulation 2007, 116 DOI: 10.1161/circ.116.suppl_16.ii_799.
  • Abstract 3775: Average Blood Glucose and Mortality in Patients Hospitalized with Acute Myocardial InfarctionKosiborod M, Inzucchi S, Krumholz H, Xiao L, Jones P, Fiske S, Masoudi F, Marso S, Spertus J. Abstract 3775: Average Blood Glucose and Mortality in Patients Hospitalized with Acute Myocardial Infarction Circulation 2007, 116 DOI: 10.1161/circ.116.suppl_16.ii_858-c.
  • La diabetes y las nuevas insulinasInzucchi S, Rolla A, Umpierrez G. La diabetes y las nuevas insulinas The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e1-e1. DOI: 10.1210/jcem.92.3.9995.
  • Diabetes and New InsulinsInzucchi S, Rolla A, Umpierrez G. Diabetes and New Insulins The Journal Of Clinical Endocrinology & Metabolism 2007, 92: e2-e2. DOI: 10.1210/jcem.92.3.9996.
  • Physiology and Pathophysiology of the Parathyroid Glands and Preoperative EvaluationHolt E, Inzucchi S. Physiology and Pathophysiology of the Parathyroid Glands and Preoperative Evaluation 2007, 235-243. DOI: 10.1007/978-3-540-68043-7_19.
  • Chapter 26 Type 2 Diabetes Therapy: Choosing Oral AgentsInzucchi S. Chapter 26 Type 2 Diabetes Therapy: Choosing Oral Agents 2006, 332-342. DOI: 10.1016/b978-1-4160-0273-4.50031-x.
  • Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imagingBax J, Bonow R, Tschöepe D, Inzucchi S, Barrett E. Early detection of coronary heart disease in diabetic patients without symptoms of coronary artery disease: implications for expanded use of myocardial perfusion imaging British Journal Of Diabetes 2005, 5: 283-288. DOI: 10.1177/14746514050050050801.
  • Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill PatientsGoldberg P, Roussel M, Inzucchi S. Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients Diabetes Spectrum 2005, 18: 188-191. DOI: 10.2337/diaspect.18.3.188.
  • Oral Agents for Type 2 Diabetes: An UpdateKimmel B, Inzucchi S. Oral Agents for Type 2 Diabetes: An Update Clinical Diabetes 2005, 23: 64-76. DOI: 10.2337/diaclin.23.2.64.
  • Chapter 87 Endocrine Emergencies: Hypoglycemic and Hyperglycemic CrisesInzucchi S, Kinder B. Chapter 87 Endocrine Emergencies: Hypoglycemic and Hyperglycemic Crises 2005, 789-799. DOI: 10.1016/b978-0-7216-0139-7.50091-0.
  • Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic SubjectsWackers F, Young L, Inzucchi S, Chyun D. Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects Diabetes Care 2005, 28: 232-233. DOI: 10.2337/diacare.28.1.232.
  • Selling Root Canals: Lessons Learned From Implementing a Hospital Insulin Infusion ProtocolGoldberg P, Inzucchi S. Selling Root Canals: Lessons Learned From Implementing a Hospital Insulin Infusion Protocol Diabetes Spectrum 2005, 18: 28-33. DOI: 10.2337/diaspect.18.1.28.
  • Screening for coronary artery disease in diabetic patients: The DIAD studyInzucchi S, Young L, Chyun D, Wackers F. Screening for coronary artery disease in diabetic patients: The DIAD study British Journal Of Diabetes 2004, 4: 317-319. DOI: 10.1177/14746514040040050501.
  • 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarctionKosiborod M, Rathore S, Wang Y, Inzucchi S, Masoudi F, Havranek E, Foody J, Krumholz H. 885-6 Prognostic implications of admission hyperglycemia in elderly patients with acute myocardial infarction Journal Of The American College Of Cardiology 2004, 43: a241. DOI: 10.1016/s0735-1097(04)91025-x.
  • Applying the Lessons of the DPP to Clinical PracticeInzucchi S, Sherwin R. Applying the Lessons of the DPP to Clinical Practice Clinical Diabetes 2003, 21: 91-92. DOI: 10.2337/diaclin.21.2.91.
  • Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD studyWackers F, Young L, Inzucchi S, Chyun D, Davey J. Detection of ischemia in asymptomatic diabetics: Preliminary results of the DIAD study Journal Of The American College Of Cardiology 2003, 41: 409. DOI: 10.1016/s0735-1097(03)81197-x.
  • Primary Pulmonary Hypertension and Thyroid DiseaseNakchbandi I, Inzucchi S, Wirth J. Primary Pulmonary Hypertension and Thyroid Disease CHEST Journal 2000, 118: 1224-1225. DOI: 10.1016/s0012-3692(15)37735-7.